H ypertension is the most common modifiable risk factor for cardiovascular disease, and treatment lowers the risk of stroke, renal disease, heart failure, cardiac disease, and death. 1,2 Despite the impact that lowering blood pressure (BP) has on clinical outcomes, <50% of patients achieve BP <140/90 mm Hg because of complex patient and system factors.
H adherence in the ED has previously been limited to patient report, and other adherence measures, such as prescriptions refills, pill counts, and surveys, have not been validated in the ED setting. [12] [13] [14] Accurately identifying antihypertensive adherence and identifying a relationship between elevated BP among patients who seek ED care may provide valuable clinical insight into antihypertensive therapy and identify patients and populations likely to benefit from additional intervention. Therefore, the primary objective of this study was to test the hypothesis that higher antihypertensive medication adherence, biochemically assessed by a liquid chromatography mass spectrometry blood assay, would be associated with lower BP in the ED setting after adjusting for multiple patient demographic and clinical factors.
Methods
We conducted a prospective, cross-sectional evaluation of a convenience sample of patients with treated hypertension who sought care at the Vanderbilt University Medical Center (VUMC) Adult ED. The Institutional Review Board reviewed and approved the study, and all patients provided written informed consent and were offered $5 for participating.
Study Population and Procedures
Adult patients (≥18 years old) who were seen in the VUMC Adult ED from July 1, 2012 to April 25, 2013 were eligible if they had a diagnosis of hypertension recorded in their electronic medical record, were prescribed at least 1 of 14 common antihypertensive medications detected by the mass spectrometry assay (Table S1 in the online-only Data Supplement), and had a VUMC primary care provider. The study enrolled patients with a VUMC primary care provider to allow review of medication, clinical, and demographic information from clinic visits, pharmacy notes, and patient summaries in the electronic health record; it also allowed confirmation of the most recent primary care clinic date, and it reduced the risk of potential unmeasured confounders that might have led patients to seek a primary care provider at a tertiary care center.
Patients were excluded if they did not have a peripheral intravenous access or declined a blood draw, were pregnant, were unable to provide consent, had previously been enrolled in this study, sought care in the ED for acute stroke or alcohol withdrawal, or had been in the ED for >36 hours. Trained research assistants screened patients who presented to the ED with the above inclusion criteria via the electronic medical record during working hours (20 h/d during weekdays and 10 h/d on weekends).
Research assistants enrolled participants, obtained written informed consent, and collected demographic data, clinical information, and medication lists. The number and type of prescribed antihypertensive medications were obtained through a combination of standardized interview questions and review of the electronic medical record. Where there was apparent discrepancy between patient-reported medications and medications listed in the electronic health record, consensus was achieved through additional review of clinic notes, discharge summaries, electronic prescriptions, and clinical communications in the electronic health record, discussion with the patient, and calling outpatient pharmacies. There was no case in which consensus of the medication list among these sources was not achieved. Research assistants obtained blood for the mass spectrometry assay from either an existing peripheral intravenous access, venipuncture, or blood sample (serum) remaining from the clinical encounter. Participants completed the Adherence to Refills and Medications Scale (ARMS ;  Table S2 ), 12 measures of numeracy, 15 and health literacy.
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Antihypertensive Adherence by Assay
The liquid chromatography mass spectrometry assay is a sensitive and specific biochemical assessment of adherence to multiple cardiovascular medications. Details of the assay's analytic and clinical validation among patients who received cardiovascular medication under medical supervision have been described previously. 17 For the purposes of this study, we considered 14 commonly prescribed medications that are included on the assay when defining antihypertensive adherence: amlodipine, atenolol, carvedilol, clonidine, diltiazem, hydrochlorothiazide, hydralazine, lisinopril, losartan, metoprolol, nifedipine, ramipril, valsartan, and verapamil. For each of these antihypertensives, previously published detection thresholds were used to determine drug presence or absence. 17 The ratio of the number of antihypertensives detected in blood to the number of antihypertensives that had been prescribed (of the 14 assay antihypertensives) was used to categorize patients as adherent (ratio=1.0) or nonadherent (ratio<1.0). For example, a patient prescribed lisinopril, hydrochlorothiazide, and amlodipine who had all three of these medications detected by the assay was given a ratio of 1 and was classified as adherent. There were no cases in which patients were falsely classified as adherent because of a discrepancy between the prescribed and detected antihypertensive medications (eg, amlodipine was prescribed, but lisinopril was detected).
BP in the ED
In the ED, BP was measured approximately every 2 hours as part of clinical care using the oscillometric method by clinical care technicians, who recorded the information in the electronic medical record. Clinical care technicians are trained to obtain BP using an appropriately sized BP cuff at the level of the patient's heart and with the patient seated on a gurney. Up to 10 measures of BP obtained during the course of clinical care were recorded. Each patient also had a single measure of BP using the oscillometric method performed by trained research staff. The research BP measurement was obtained in a standard fashion using the appropriately sized BP cuff at heart height with patients in either seated or semi-recumbent position (sitting up on a gurney). The primary outcome was the average ED systolic BP (SBP), which was computed using all clinical BP measures, but excluded the first BP measure (triage BP) and any measures obtained after administration of antihypertensive medications, furosemide, or nitroglycerin via any route.
Covariates
The following covariates were included in multivariable models as potential confounders based on previous causal evidence [18] [19] [20] : age, sex, race (white, non-white), health insurance (commercial; Medicare, Medicaid, or federal; self-pay or unknown), comorbid conditions measured by the Elixhauser index, 21 
Statistical Analyses
Patient demographics and clinical characteristics are reported using means and SD or medians and interquartile ranges for continuous variables and frequencies and proportions for categorical variables. Medication adherence decreases with increasing number of prescribed antihypertensives, 7 and 3 antihypertensives, including a thiazide diuretic or equivalent, may identify patients with resistant hypertension 23 ; therefore, we evaluated for evidence of interaction between adherence and the number of prescribed medications (<3, ≥3 antihypertensives). Because we found strong evidence for an interaction (interaction P value <0.001), all analyses were stratified by <3 or ≥3 antihypertensives.
The unadjusted relationship between medication adherence and mean SBP was examined using box plots; Wilcoxon rank-sum tests were performed to examine whether differences were statistically significant. We performed multiple linear regression models to compare mean SBP for patients classified as adherent versus nonadherent, after adjusting for the above covariates. For 18 subjects with missing numeracy, we performed multiple imputations. 24 A 2-sided α of 0.05 was used for all analyses. 25 By post hoc calculations, 260 subjects provided 80% power with an α of 0.05 to detect a difference in blood pressure by adherence of 14 mm Hg.
Sensitivity Analyses
We examined the sensitivity of these results to the definitions of the outcome and exposure. First, we varied the outcome definition to determine the association of antihypertensive adherence measured by the blood assay with the single SBP obtained by a research assistant. Then, we examined 2 alternative definitions of medication adherence. The first alternative definition was patient report of medication adherence via the ARMS, which is 12-item patient-reported measure of global adherence that assesses medication-taking and refilling behaviors on a 4-point Likert-like scale (Table S2) . 12 The ARMS does not specify a time frame over which the participant is to base his/her responses, nor does it specify type of medications. Consistent with previous work, the minimum ARMS summary score of 12 was used to classify patients as adherent, and >12 was used to define nonadherence. 26 To examine which measure of adherence explained a statistically significantly larger proportion of variance in mean SBP, the likelihood ratio was computed comparing a model with both the assay and ARMS to a model with only the ARMS.
The second definition of medication adherence combined both objective and subjective adherence measures, the assay and ARMS, respectively. Each subject was categorized as 1 of 4 mutually exclusive levels: (1) adherent by both the assay and ARMS; (2) adherent by the assay only; (3) adherent by the ARMS only; and (4) nonadherent by both. Multiple linear regression was performed using the 4-level adherence variable as the exposure, stratified by the number of prescribed antihypertensives and covariates as described above.
Results
A total of 2011 patients were screened, and of these, 1538 were excluded for ineligibility and 172 declined to participate ( Figure S1 ). Of the 301 subjects enrolled, 2 were subsequently excluded, one because propranolol was prescribed for headaches and the other because the patient did not have a VUMC primary care provider. Thirty-eight patients were given medication that lowers BP as part of their clinical care immediately after the triage SBP measurement, leaving 261 patients in the primary analyses. There were 176 patients (67.4%) prescribed <3 antihypertensives, and 85 patients (32.6%) prescribed ≥3 antihypertensives ( Figure S1 ), of which 78 (91.7%) were prescribed hydrochlorothiazide, amlodipine, or nifedipine.
Population Characteristics
Demographics and clinical characteristics of patients included in the primary analyses are reported in Table 1 , stratified by the number of antihypertensive medications that were prescribed, based on medication reconciliation. Overall, mean age was 59.2 years (SD, 11.4 years), 53.3% were female, 63.2% were white, and 19.5% had not completed high school. Thirty-four patients (13.0%) had low health literacy defined as a Brief Health Literacy score ≤9, and 127 (52.3%) had low numeracy, defined as a Subjective Numeracy Scale score ≤35. Most patients, 161 (62.7%), reported that they had been diagnosed with hypertension for >10 years. Comorbidities were common: 37.9% had diabetes mellitus, and 24.9% had chronic renal insufficiency. Patients sought ED care for a wide range of symptoms, including 85 (32.6%) with cardiovascular chief complaints of chest pain, shortness of breath, arrhythmia, or palpitations, and 9 specifically for hypertension. The most common chief complaints were chest pain, dyspnea, abdominal pain, and generalized weakness; there was no difference in the frequency of these complaints between the 2 groups (P>0.05 for each chief complaint). No patients sought care for refill of medication.
Among patients who were confirmed to have been prescribed ≥3 antihypertensive medications, patients commonly underestimated the number of their prescribed antihypertensive medications; the mean patient-reported number of antihypertensive medications was 2.6 (SD, 1.0), and of the 85 patients confirmed to be prescribed ≥3 antihypertensive medications, 38 (44.7%) reported they were prescribed <3.
Prescribed Antihypertensives and Assay-Based Medication Adherence
The number of prescribed antihypertensives and number of antihypertensives detected by the blood assay are displayed in Table 2 . The mean number of prescribed antihypertensives was 2.1 (SD, 1.1; median, 2.0; interquartile range, 1.0-3.0), and the mean number of antihypertensives detected by the blood assay was 1.8 (SD, 1.0; median, 2.0, interquartile range, 1.0-2.0). There were clinically important differences in adherence among the antihypertensives, with fewer than 80% of patients having detectible medication levels for clonidine, hydrochlorothiazide, nifedipine, and ramipril. On the basis of blood assay results, 79.0% of patients prescribed <3 antihypertensives were adherent, and 58.8% of patients prescribed ≥3 antihypertensives were adherent as defined by an adherence ratio of 1.0.
There were 85 patients who did not report when they last took their BP medications, and 5 patients reported that they had stopped taking their medication >4 days prior because of cost or side effects. Of the remaining 171 patients who reported taking their BP medication within the 96 hours before the ED visit, the mean time between ingestion and blood draw was 15.8 hours (SD, 11.4 hours), and median time was 12.3 hours (interquartile range, 7.25-21.2 hours).
Relationship Between Assay Adherence and BP
Mean SBP in the ED was 137.4 mm Hg (SD, 23.4 mm Hg), and patients had on average 3.2 BPs measured (SD, 1.8) over a mean duration of 270 minutes in the ED (SD, 120 minutes) . Table S3 . Figure 2 illustrates results of the multiple linear regression models between medication adherence measured by the blood assay and SBP, stratified by number of prescribed antihypertensives, and adjusted for covariates. Results of analyses using the ARMS as the measure of antihypertensive adherence are included for comparison. Among 176 patients prescribed <3 antihypertensives, mean SBP was no different from patients classified as being nonadherent (+2. 
Sensitivity Analyses
To test the sensitivity of these findings to the outcome definition, we conducted the same analyses using the research SBP measure (n=297) and found essentially the same results (Table S4 ; Figure S2 ). Mean research SBP was 136.7 mm Hg (SD, 24.4 mm Hg) or <1 mm Hg lower than mean ED SBP. For patients prescribed <3 antihypertensives, research SBP was −4.3 mm Hg (95% CI, −12.6 to 3.9 mm Hg; P=0.30) for adherent versus nonadherent by the assay. For patients prescribed ≥3 antihypertensives, research SBP was −20.8 mm Hg (95% CI, −31.6 to −10.0 mm Hg; P<0.001) for adherent versus nonadherent by the assay.
When adherence was measured by the ARMS, there was not a detectible relationship between medication adherence and SBP (Table 3; Table S3 and Figure S3 ). By the ARMS, 59 patients (22.6%) reported complete adherence to refilling and medication-taking behaviors. The assay explained more variance in mean SBP than the ARMS (P=0.003), although the 4-level measure of adherence derived from combining the assay and ARMS was also strongly associated with mean SBP in a step-wise fashion among those prescribed >3 antihypertensives ( Figure 3 ; Table S5 ).
Discussion
In this cross-sectional study of adults with treated hypertension in the ED, among patients prescribed ≥3 antihypertensives, mean SBP was ≈20 mm Hg lower for patients found to be adherent by a blood assay than for those determined to be nonadherent. There was, however, no detectible difference in BP by adherence among patients prescribed <3 antihypertensive medications. Although this is the first study to use a blood assay to measure antihypertensive adherence in an ED setting, patterns of adherence by number and class of prescribed antihypertensive medications and the relationship between adherence and SBP were similar to previous studies conducted in outpatient specialty clinics and among patients with resistant hypertension, [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] supporting the validity of our findings.
By the liquid chromatography mass spectrometry assay, nearly 28% of patients were nonadherent to prescribed antihypertensive medications despite having a primary care physician and health insurance. Adherence was generally highest for angiotensin II receptor blockers and angiotensin-converting enzyme inhibitors, followed by calcium channel blockers, diuretics, and β-blockers, similar to patterns of adherence by antihypertensive classes found in previous work. [37] [38] [39] [40] [41] [42] [43] In this study, fewer than 80% of patients who were prescribed hydrochlorothiazide, clonidine, ramipril, or nifedipine had detectible blood levels at the time of study enrollment. In post hoc analyses, patients prescribed hydrochlorothiazide had 2.7 (95% CI, 1.5-4.9) greater odds of nonadherence compared with patients who were not prescribed hydrochlorothiazide after adjusting for age, sex, race, insurance, health literacy, numeracy, and education, which is similar to recent work conducted in hypertension clinics. 38 Urinary frequency, orthostatic hypotension, and sexual dysfunction may contribute to the estimated 44.2% nonadherence to hydrochlorothiazide, 37, 38 and oral clonidine dosing frequency is an independent risk factor for nonadherence. 42 Although adherence to angiotensin-converting enzyme inhibitors is generally better than other antihypertensive classes, 50% adherence to ramipril is similar to adherence measured by a urine assay among patients with resistant hypertension in a clinical trial. 44 Although suboptimal, adherence to nifedipine in this study was higher than the 14% to 68% range of adherence to calcium channel blockers found in previous studies. 39 Therapeutic drug monitoring of medication concentrations in urine and blood as a measure of adherence is becoming more widely available [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] ; in addition, understanding and using results therapeutic drug monitoring is relevant to a wide range of clinicians. Complete nonadherence defined by lack of detection of any prescribed antihypertensive medications ranged from 10% to 54% in studies conducted in specialty clinics or clinical trials. [31] [32] [33] [34] [35] [36] [37] [38] Among patients who described themselves as adherent, ≈33% were completely nonadherent according to therapeutic drug monitoring, 32, 35 which is similar to our findings of 32% complete nonadherence among the 202 patients who reported being adherent by the ARMS in this study. The difference of ≈20 mm Hg between adherent and nonadherent patients prescribed ≥3 antihypertensives in this study is also similar to the 18 mm Hg difference between adherent and nonadherent patients referred to a hypertension specialty clinic. 33 The assay provides the most clinical value for patients with elevated BP who report being adherent; in these patients, the assay distinguishes medication nonadherence from medication ineffectiveness (Figure 2 ). The assay is more closely associated with SBP than the ARMS, possibly because these 2 measures address different aspects of medication adherence. In preliminary work comparing adherence measured *Medications for which <80% of patients had detectable blood levels. †Wilson 95% CIs computed for the proportion of adherent subjects for each antihypertensive. by a urine assay and the 4-item Morisky survey, which is closely related to the ARMS, there was little to no correlation between the 2 measures of adherence. 36 In this study, 27.6% of patients were nonadherent according to the assay, compared with 77.4% of patients who were nonadherent according to the ARMS. This apparent discrepancy reflects differences in the aspects of adherence addressed by an assay versus patient report. The assay is a sensitive measure of adherence over the prior 24 to 36 hours and is closely tied to SBP, whereas the ARMS relies on patient report of medication-taking and medication-refilling behaviors of medication in general without a time frame. Despite their weak relationships to each other, we found that combining information from both the assay and ARMS provided additional information beyond that available only from the assay.
Antihypertensive nonadherence should be explored as a potential cause of consistently or markedly elevated SBP among patients with hypertension in the ED. Hypertensionrelated ED visits are common and becoming more frequent, with a >20% increase between 2006 and 2012. 8 Of the >136 million ED visits annually in the United States, 27.2% of patients had BP ≥140/90 mm Hg, and 16.3% had BP ≥160/100 mm Hg. 45 General medication nonadherence is itself associated with ED visits, 46, 47 and high BP in the ED often persists after discharge home. [48] [49] [50] Because uncontrolled BP is rarely symptomatic, and elevated BP is highly prevalent across ED chief complaints, 51 we did not restrict enrollment to patients with hypertension-related concerns; overall, 33% of patients reported a chief complaint of chest pain, dyspnea, or hypertension. Patients seeking emergency care for conditions unrelated to hypertension who are found to have markedly elevated BP may gain the most from its identification because they are the least likely to be aware of it. This study was conducted at an academic referral center, but patient characteristics were similar to those found in US academic EDs. 9 We found patterns and prevalence of nonadherence similar to those of specialty and other outpatient settings, and the relationship with SBP was similar to previous work, suggesting that patterns of nonadherence among patients with hypertension who seek ED care have some characteristics in common with patients in outpatient and specialty clinic settings.
At a minimum, consistently elevated BP during an ED visit should be discussed with patients and integrated into their follow-up plan. Medication nonadherence should routinely be explored with neutral, nonjudgmental language that acknowledges the difficulties patients face in managing medications for chronic illness, and post-ED follow-up should be emphasized. Brinker et al 32 noted that among 16 patients from a hypertension who initially reported being adherent and were later provided results of serum tests confirming nonadherence, issues such as difficulty remembering to take medications, debilitating fatigue attributed to medication, and inability to pay for medications were subsequently reported. After nonadherence was identified and addressed, SBP in these patients improved by an average of 46 mm Hg without a change in the number of prescribed antihypertensives. 32 Our study has limitations that should be noted. Interpretation of assay results should take into consideration factors that can affect blood concentration, including medication absorption, metabolism, and elimination, time since last dose, concurrent drug ingestion, diet, exercise, infection, and genetics. For example, patients prescribed an antihypertensive with a relatively short half-life but long duration of effect, such as losartan, could miss multiple doses and be classified as nonadherent while still experiencing BP-lowering effect from the medication. Validations studies of the assay did not reveal evidence that processing or storage conditions impact drug detection, 17 but these factors may influence assay results for medications, such as nifedipine, which decomposes in ultraviolet light. Thresholds for assay detection were set according to published ranges in healthy subjects, and the assay was validated among hospitalized patients who were administered these medications 17 ; despite this, the difference between when patients stop taking medication as prescribed and when they no long experience BP reduction from the medication may in part explain the apparent lack of relationship between adherence and SBP among patients prescribed <3 antihypertensive medications. We did not exclude patients who reported taking nonsteroidal anti-inflammatory medications or decongestants before arrival; post hoc analysis excluding these patients did not change point estimates, although with reduced sample size the CIs were wide. Our findings should also be considered in light of use of a convenience sample of patients enrolled at an academic medical center because these patients may not be reflective of patients with hypertension who seek care in other ED settings. Finally, white coat adherence, or patients taking medication before going to the ED, may have occurred.
Perspectives
Biochemical assessment of antihypertensive adherence is closely tied to SBP in the ED among patients with hypertension prescribed ≥3 BP medications. Antihypertensive nonadherence should be explored as a potential cause of consistently or markedly elevated SBP in the ED among patients with hypertension.
